Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa + carfilzomib + dexamethasone
isatuximab-irfc with carfilzomib and dexamethasone · Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after one to three prior lines of therapy.
LAMPGEN ANALYSIS
Why it matters
This adds an anti-CD38 antibody to a carfilzomib and dexamethasone backbone in relapsed myeloma.
What research teams should watch
Reconcile earlier regimens and synchronize antibody infusion with the carfilzomib schedule.
PRIMARY RECORDS